Manufacturer
ORION CORP
Contents
Per 50/12.5/200 FC tab Levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg.
Indication
Idiopathic Parkinson's disease: Substitute for IR carbidopa/l-dopa & entacapone; replace IR carbidopa/l-dopa therapy (w/o entacapone) when patients experience the signs & symptoms of end-of-dose ''wearing-off''.
Instruction
May be taken with or without food.
Drug interaction
Symptomatic postural hypotension may occur w/ antihypertensives. MAOI, TCAs or noradrenaline reuptake inhibitors. Selegiline. Loss of therapeutic response w/ dopamine-receptor antagonists (eg, antipsychotics & antiemetics), phenytoin, papaverine. Warfarin. Fe prep (take 2-3 hr apart). Impaired absorption w/ high-protein diet.
Malaysia
